At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Omega-3 Fatty Acids as a Treatment-adjunct in Adolescent Patients With Major Depressive Disorder Exhibiting Partial Response to SSRI Medications: An Open-label Neuroimaging Trial
In Brief
A Phase 3 clinical trial evaluating Low Dose Fish Oil and High Dose Fish Oil for Major Depressive Disorder. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.
Study Details
Timeline
Interventions
Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)